AvicannaAVCNF -2.55%53 Days Payable is 268.25 as of Mar. 2026, which is 64% below its 10-year median of 749.29. GuruFocus rates AVCNF with a GF Score™ of 53/100 and a GF Value™ of $0.20 (Possible Value Trap). The stock has 2 warning signs investors should review. Among 920 Drug Manufacturers companies, Avicanna ranks better than 88.91% on this metric.
Avicanna's average Accounts Payable for the
three
months ended in Mar. 2026 was $6.09 Mil. Avicanna's Cost of Goods Sold for the
three
months ended in Mar. 2026 was $2.07 Mil.
Hence, Avicanna's Days Payable for the
three
months ended in Mar. 2026 was 268.25.
The historical rank and industry rank for Avicanna's Days Payable or its related term are showing as below:
AVCNF'
s Days Payable Range Over the Past 10 Years
Min: 219.81 Med: 749.29 Max: 15930.33
Current: 243.21
During the past 10 years, Avicanna's highest Days Payable was 15930.33. The lowest was 219.81. And the median was 749.29.
AVCNF's Days Payable is ranked better than 88.91% of 920
companies
in the Drug Manufacturers industry
Industry Median: 90.835
vs AVCNF: 243.21
Avicanna's Days Payable
increased
from Mar. 2025 (243.29) to Mar. 2026 (268.25).
It may suggest that Avicannadelayed paying its suppliers.
Avicanna Days Payable Related Terms
Avicanna Days Payable Historical Data
* Premium members only.
The historical data trend for Avicanna's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Avicanna's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Avicanna Days Payable vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Avicanna's Days Payable distribution charts can be found below:
* The bar in red indicates where Avicanna's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Avicanna's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Avicanna (AVCNF) has a Days Payable of 268.25 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Avicanna and its competitors. This is 64% below median its historical median of 749.29. Over the past decade, Avicanna's Days Payable has ranged from 219.81 to 15,930.33. According to the industry distribution chart, Avicanna ranks #102 out of 920 companies in the Drug Manufacturers industry, placing it in the top 11.1%.
Is Avicanna's Days Payable too high?
Avicanna's current Days Payable of 268.25 is 64% below median its 10-year median of 749.29. Over the past 10 years, this metric has ranged from a low of 219.81 to a high of 15,930.33. The Drug Manufacturers industry median Days Payable is 90.84. Avicanna's value of 268.25 is 195.3% above this industry median. Based on the distribution chart, Avicanna ranks #102 out of 920 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Avicanna has a GF Score™ of 53/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Avicanna's Days Payable compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Avicanna ranks #102 out of 920 companies for Days Payable. This places Avicanna in the top 11% of its industry — outperforming the majority of peers. The industry median Days Payable is 90.84. Avicanna's value of 268.25 is 195.3% above this benchmark. Historically, Avicanna's own Days Payable has ranged from 219.81 to 15,930.33 over the past decade. While the company's 10-year median is 749.29 vs. the industry median of 90.84, Avicanna has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Drug Manufacturers company?
The median Days Payable among Drug Manufacturers companies is 90.84, based on 920 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Avicanna's current Days Payable of 268.25 is 195.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Avicanna and its competitors. For the Drug Manufacturers industry, the median Days Payable is 90.84 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Avicanna's current Days Payable is 268.25, which is 64% below median its own 10-year median of 749.29. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Avicanna stock overvalued right now?
Based on GuruFocus' analysis, Avicanna (AVCNF) is currently considered Possible Value Trap. The stock's GF Value™ is $0.20, compared to a current price of $0.09 — trading 57.5% below its estimated fair value. The current Days Payable is 268.25, which is 64% below median its 10-year median of 749.29 and 195.3% above the Drug Manufacturers industry median of 90.84. Avicanna's overall GF Score™ is 53/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Avicanna (AVCNF), the current Days Payable is 268.25 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Avicanna (AVCNF) Overvalued in 2026?
Based on GuruFocus' analysis, Avicanna stock appears to be undervalued.
The current stock price of $0.09 is trading 57.5% below its estimated GF Value™ of $0.20.
GuruFocus considers Avicanna to be Possible Value Trap.
Key valuation signals for AVCNF:
Days Payable: 268.25 (64% below median its 10-year median of 749.29)
GF Value™: $0.20 vs. price of $0.09 (57.5% below fair value)
Industry Position: 195.3% above the Drug Manufacturers median (#102 of 920)
No single metric tells the full story. See the AVCNF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Avicanna Inc is a commercial-stage international biopharmaceutical company focused on the development, advancement, and commercialization of evidence-based cannabinoid-based products and formulations for the medical and pharmaceutical market segments. It has three operating segments: Canada, International, and Corporate. It generates the majority of its revenue from Canada.
53GF Score
Get the complete analysis for AVCNF
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AVCNF has been successfully added to your 
